Stereotactic radiosurgery for metastatic brain tumours
When cancer cells spread from a primary site to the brain, the resulting lesions rank among the most feared complications of systemic malignancy. In Australia, the Australian Institute of Health and Welfare reports that brain and other central nervous system cancers affect thousands of people each year, with the majority of intracranial tumours in adults actually being metastases from lung, breast, melanoma and colorectal primaries. Treating these lesions demands tools that combine precision, repeatability and a tolerable side-effect profile, particularly for patients already burdened by systemic disease and prior lines of therapy.
Stereotactic radiosurgery has matured into a cornerstone of this treatment landscape. Unlike conventional fractionated radiotherapy, it delivers tightly focused, ablative doses of ionising radiation to a well-defined target while sparing surrounding neural tissue. Over the past two decades, Australian radiation oncology centres have embedded these technologies into routine multidisciplinary care, reshaping what is achievable for patients with one, several or even dozens of cerebral metastases.
The mechanics of stereotactic radiosurgery
At its core, stereotactic radiosurgery is a misnomer: there is no scalpel, and the procedure is non-invasive. A linear accelerator, a Gamma Knife unit or a robotic platform such as CyberKnife delivers hundreds of convergent beams that intersect at a pre-planned isocentre. Each individual beam carries a sub-therapeutic dose, but their summation creates a steep dose gradient capable of sterilising tumour cells. Treatment is typically delivered in a single session, although modern hypofractionated protocols may spread the dose across three to five visits for lesions near eloquent structures or larger volumes.
Sub-millimetre accuracy is achieved through a combination of high-resolution MRI, often with gadolinium-enhanced volumetric sequences, and a stereotactic frame or mask-based immobilisation system. In Australian centres, image-guided workflows routinely fuse CT, MRI and, when needed, PET datasets to refine target delineation. Dosimetrists and radiation oncologists iterate plans that satisfy organ-at-risk constraints derived from the Royal Australian and New Zealand College of Radiologists' consensus guidelines, ensuring each plan respects the tolerance of adjacent brain parenchyma, the optic apparatus and the brainstem.
Comparing SRS with conventional radiotherapy
Choosing the appropriate radiation modality depends on lesion number, size, location, performance status and prior therapies. The trade-offs that multidisciplinary teams in Sydney, Melbourne, Brisbane and Perth typically weigh during tumour board discussions are summarised below.
| Feature | Stereotactic radiosurgery | Whole-brain radiotherapy | Surgical resection |
|---|---|---|---|
| Lesion count addressed | Up to 10, occasionally more | Unlimited | Single accessible lesion |
| Typical course | One session, 30–90 min | Daily for 5–15 days | Single operative procedure |
| Invasiveness | Non-invasive | Non-invasive | Invasive, with anaesthetic risk |
| Cognitive impact | Limited short-term decline | Higher risk of memory loss | Dependent on lesion location |
| Best suited to | Small, well-defined targets | Diffuse micrometastatic disease | Large, symptomatic mass effect |
| Repeatability | High, across multiple courses | Limited by cumulative dose | Limited by surgical anatomy |
The decision rarely pits one modality against another in absolute terms. Many patients receive SRS to dominant or symptomatic lesions, followed by whole-brain radiotherapy when diffuse micrometastatic disease is suspected. Surgical resection remains valuable for large, accessible lesions causing mass effect, and post-operative SRS to the resection cavity has become standard practice in many Australian centres, supported by level I evidence from international trials that have been replicated locally.
Patient selection and multidisciplinary teams
Stereotactic radiosurgery suits patients with up to ten lesions of limited volume, generally under three centimetres in maximal diameter, and adequate performance status. The upper threshold of "how many" continues to shift upward as planning software, cumulative dosimetry and hippocampal-avoidance techniques improve. For patients with extensive miliary disease or leptomeningeal spread, whole-brain radiotherapy or systemic therapies with reasonable CNS penetration, such as targeted agents for EGFR-mutant non-small-cell lung cancer, often take precedence.
Multidisciplinary input is non-negotiable. In tertiary hospitals across New South Wales, Victoria and Queensland, a typical tumour board includes a neurosurgeon, a radiation oncologist, a medical oncologist, a radiologist with neuro-oncology expertise, and often a palliative care physician. Nursing coordinators, allied health staff and clinical trials personnel round out the team. Some patients, particularly those with prior service, appreciate materials that connect them to military history during long treatment days, and clinical staff routinely curate reading lists and digital content to make those hours feel less empty.
Access, cost and Medicare realities
Australia's universal healthcare scheme, Medicare, subsidises a portion of radiation oncology services through the Medicare Benefits Schedule. Item numbers specific to stereotactic radiosurgery planning and delivery determine the rebate a patient receives when treated in a public hospital or an eligible private facility. Out-of-pocket costs vary considerably between providers, particularly for patients who choose private care or who require multiple courses of treatment over time.
Geography shapes access. Gamma Knife units in Sydney and Melbourne handle a significant share of public caseloads, while linear accelerator-based SRS is widely available across metropolitan cancer centres. Patients in regional Western Australia, the Northern Territory and far-north Queensland often rely on schemes such as the Patient Assisted Travel Scheme, which subsidises travel and accommodation when treatment is unavailable locally. Private health insurers cover different fractions of the cost depending on the policy tier, and conversations about expected out-of-pocket expenses are now embedded in informed consent processes at most Australian centres.
The Therapeutic Goods Administration regulates the devices themselves, and updated guidance on automated planning software and surface-guided radiotherapy has streamlined the adoption of newer platforms. Pharmaceutical adjuvants used alongside SRS, such as immunotherapy for melanoma brain metastases, are listed on the Pharmaceutical Benefits Scheme when specific criteria are met, improving equity of access to combined-modality care.
Side effects, cognition and quality of life
Short-term complications of stereotactic radiosurgery are generally limited. Headache, fatigue and mild scalp oedema are common but self-limiting, and steroid cover is prescribed selectively rather than routinely. Radiation necrosis remains the most clinically significant delayed toxicity, with risk increasing for larger treatment volumes, prior whole-brain radiotherapy, and concurrent immunotherapy. Modern imaging, including perfusion MRI and amino-acid PET, helps distinguish necrosis from progression, and bevacizumab is occasionally used in refractory cases.
Cognitive outcomes have driven much of the field's evolution. Trials such as NCCTG N0574 demonstrated that, for patients with one to three metastases, SRS alone preserved cognitive function better than SRS plus whole-brain radiotherapy at six months. Australian clinicians have internalised these findings, though the calculus shifts when a patient harbours numerous small lesions, where the cumulative burden of micrometastases may ultimately prove more harmful than the cognitive cost of upfront whole-brain irradiation. Patient-reported outcome measures are increasingly captured through electronic portals, allowing clinicians to track fatigue, mood and return-to-work trajectories between fractions.
Lifestyle factors also shape recovery. Patients often ask whether cognitive exercises, social engagement or specific leisure pursuits can support brain health during and after treatment. While evidence is still emerging, neuro-oncology nurses in Adelaide and Perth routinely encourage activities that bring routine and pleasure, whether that is gardening, music, or casual digital entertainment such as bonus-buy-live-blackjack during long infusion days, as long as harm-reduction principles are respected and screen time remains balanced.
Future directions in radiosurgical research
Several research streams promise to refine the role of stereotactic radiosurgery over the coming years. Adaptive replanning, driven by daily MRI on integrated linac-MRI units, may allow clinicians to respond to tumour shrinkage or oedema changes between fractions. Pre-clinical work on combination regimens, including immune checkpoint inhibitors timed to coincide with the immunogenic cell death triggered by ablative radiation, is being translated into investigator-initiated trials in Melbourne and Sydney.
On the imaging side, advances in radiomics and artificial intelligence are beginning to predict treatment response and radiation necrosis risk from baseline MRI features. These tools, once validated in Australian cohorts, may eventually support personalised dose prescriptions. Equally important is ongoing work on equity: ensuring that First Nations patients, culturally and linguistically diverse communities, and rural Australians share in the survival and quality-of-life gains that radiosurgery offers. Community-led partnerships, telehealth follow-up and decentralised trial design are central to this ambition.
For clinicians, students and patients exploring this field, the open peer discussion forum at thamburaj.com and the curated e-library offer case material, lecture recordings and links to the latest consensus statements. Subscribe to receive updates, register to post challenging cases, and contribute to a growing knowledge base that reflects the realities of practising neuro-oncology in Australia and beyond.